Approved for use through 07/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE duction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
<b>4</b> 4.2		•		Application Number	10/583,419-Conf. #3702	
IN	<b>IFORMATION</b>	1 DI	SCLOSURE	Filing Date	September 28, 2007	
S	STATEMENT BY APPLICANT			First Named Inventor	Christian Hubschwerlen	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	65507(41925)	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
iniuais	No. <sup>1</sup>		(VIIII DD 1111	Applicant of Cited Document	Figures Appear	
	AA*	US 2004/0132764	07-08-2004	Locher		
	<u> </u>					
			<u> </u>			
					·	
•						

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	1
	ВА	KR-10 2000 0067306	11-15-2000	Korea Institute of Science and Technology		V
	вв	WO-03/031441-A1	04-17-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	вс	WO-2004/096221-A1	11-11-2004	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie.		
	BD	WO-2005/023801-A1	03-17-2005	Morphochem AG		
	BE	WO-01/46164-A1	06-28-2001	Ortho-McNeil Pharmaceutical, Inc.		

Examiner	Date	
Signature	Considered	
		النادات المستحرب بين بالمستحرب المستحرب المستحرب المستحرب المستحرب المستحرب المستحرب المستحرب المستح

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/583,419-Conf. #3702	
11	VFORMATION	I DIS	SCLOSURE	Filing Date	September 28, 2007	
S	STATEMENT BY APPLICANT			First Named Inventor	Christian Hubschwerlen	
				Art Unit	N/A	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	65507(41925)	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	CA	C. Hubschwerlen et al., "Design, Synthesis and Biological Evaluation of Oxazolidinone-Quinolone Hybrids", <i>Bioorganic &amp; Medicinal Chemistry</i> , Vol. 11, pgs. 2313-2319 (2003).				
	СВ	C. Hubschwerlen et al., "Structure-Activity Relationship in the Oxazolidinone-Quinolone Hybrid Series: Influence of the Central Spacer on the Antibacterial Activity and the Mode of Action", Bioorganic & Medicinal Chemistry Letters, Vol. 13, pgs. 4229-4233 (2003).				
	СС	Locher et al., "Synthesis and Antibacterial Action of Novel Quinolone-linked Oxazolidinones", 42th ICAAC (2002), poster and abstract F-1317, ICAAC 2002: San Diego, California, September 27-30, 2002.				
	CD	Hubschwerlen et al., "New Qxazolidinone-Quinolone Hybrids: Synthesis and SAR", 43rd ICAAC (2003), abstract F-2144, Chicago, IL, September 14-17, 2003.				
} 						

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.